Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

Suzanne Topalian, L. M. Muul, D. Solomon, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The potential utility of tumor-infiltrating lymphocytes (TIL) in the adoptive immunotherapy of human tumors has been suggested by murine experiments showing these cells to be 50-100 times more powerful than LAK cells in treating advanced metastatic disease. A method for the large-scale expansion of human TIL for the use of these cells in clinical trials is described in this report. TIL were successfully expanded on an experimental scale from 24 of 25 consecutive human tomors, including six melanomas, ten sarcomas, and eight adenocarcinomas. Tumors were digested enzymatically to yield single cell suspensions which were cultured in RPMI 1640 medium with 10% human serum and 1000 U/ml recombinant interleukin-2. Lymphocytes constituted from 3% to 74% of single cell tumor suspensions, and expanded from 2.9-fold to 9.1 X 108-fold over a culture period ranging from 14 to 100 days. Nine of 24 TIL cultures lysed fresh autologous tumor targets in 4 h chromium release assays. Cell surface phenotyping identified cultured TIL as activated cytotoxic/suppressor T cells. Subsequently, large-scale expansion of TIL was successful in generating more than 1010 lymphocytes in five of eight consecutive cases. Clinical trials employing the adoptive transfer of expanded TIL to patients with metastatic disease have begun.

Original languageEnglish (US)
Pages (from-to)127-141
Number of pages15
JournalJournal of Immunological Methods
Volume102
Issue number1
StatePublished - 1987
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Immunotherapy
Neoplasms
Suspensions
Clinical Trials
Lymphocytes
Adoptive Immunotherapy
Lymphokine-Activated Killer Cells
Adoptive Transfer
Chromium
Sarcoma
Interleukin-2
Melanoma
Adenocarcinoma
T-Lymphocytes
Serum

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. / Topalian, Suzanne; Muul, L. M.; Solomon, D.; Rosenberg, S. A.

In: Journal of Immunological Methods, Vol. 102, No. 1, 1987, p. 127-141.

Research output: Contribution to journalArticle

Topalian, Suzanne ; Muul, L. M. ; Solomon, D. ; Rosenberg, S. A. / Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. In: Journal of Immunological Methods. 1987 ; Vol. 102, No. 1. pp. 127-141.
@article{980b60b4cdb84453afb2ee576b2214d2,
title = "Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials",
abstract = "The potential utility of tumor-infiltrating lymphocytes (TIL) in the adoptive immunotherapy of human tumors has been suggested by murine experiments showing these cells to be 50-100 times more powerful than LAK cells in treating advanced metastatic disease. A method for the large-scale expansion of human TIL for the use of these cells in clinical trials is described in this report. TIL were successfully expanded on an experimental scale from 24 of 25 consecutive human tomors, including six melanomas, ten sarcomas, and eight adenocarcinomas. Tumors were digested enzymatically to yield single cell suspensions which were cultured in RPMI 1640 medium with 10{\%} human serum and 1000 U/ml recombinant interleukin-2. Lymphocytes constituted from 3{\%} to 74{\%} of single cell tumor suspensions, and expanded from 2.9-fold to 9.1 X 108-fold over a culture period ranging from 14 to 100 days. Nine of 24 TIL cultures lysed fresh autologous tumor targets in 4 h chromium release assays. Cell surface phenotyping identified cultured TIL as activated cytotoxic/suppressor T cells. Subsequently, large-scale expansion of TIL was successful in generating more than 1010 lymphocytes in five of eight consecutive cases. Clinical trials employing the adoptive transfer of expanded TIL to patients with metastatic disease have begun.",
author = "Suzanne Topalian and Muul, {L. M.} and D. Solomon and Rosenberg, {S. A.}",
year = "1987",
language = "English (US)",
volume = "102",
pages = "127--141",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

AU - Topalian, Suzanne

AU - Muul, L. M.

AU - Solomon, D.

AU - Rosenberg, S. A.

PY - 1987

Y1 - 1987

N2 - The potential utility of tumor-infiltrating lymphocytes (TIL) in the adoptive immunotherapy of human tumors has been suggested by murine experiments showing these cells to be 50-100 times more powerful than LAK cells in treating advanced metastatic disease. A method for the large-scale expansion of human TIL for the use of these cells in clinical trials is described in this report. TIL were successfully expanded on an experimental scale from 24 of 25 consecutive human tomors, including six melanomas, ten sarcomas, and eight adenocarcinomas. Tumors were digested enzymatically to yield single cell suspensions which were cultured in RPMI 1640 medium with 10% human serum and 1000 U/ml recombinant interleukin-2. Lymphocytes constituted from 3% to 74% of single cell tumor suspensions, and expanded from 2.9-fold to 9.1 X 108-fold over a culture period ranging from 14 to 100 days. Nine of 24 TIL cultures lysed fresh autologous tumor targets in 4 h chromium release assays. Cell surface phenotyping identified cultured TIL as activated cytotoxic/suppressor T cells. Subsequently, large-scale expansion of TIL was successful in generating more than 1010 lymphocytes in five of eight consecutive cases. Clinical trials employing the adoptive transfer of expanded TIL to patients with metastatic disease have begun.

AB - The potential utility of tumor-infiltrating lymphocytes (TIL) in the adoptive immunotherapy of human tumors has been suggested by murine experiments showing these cells to be 50-100 times more powerful than LAK cells in treating advanced metastatic disease. A method for the large-scale expansion of human TIL for the use of these cells in clinical trials is described in this report. TIL were successfully expanded on an experimental scale from 24 of 25 consecutive human tomors, including six melanomas, ten sarcomas, and eight adenocarcinomas. Tumors were digested enzymatically to yield single cell suspensions which were cultured in RPMI 1640 medium with 10% human serum and 1000 U/ml recombinant interleukin-2. Lymphocytes constituted from 3% to 74% of single cell tumor suspensions, and expanded from 2.9-fold to 9.1 X 108-fold over a culture period ranging from 14 to 100 days. Nine of 24 TIL cultures lysed fresh autologous tumor targets in 4 h chromium release assays. Cell surface phenotyping identified cultured TIL as activated cytotoxic/suppressor T cells. Subsequently, large-scale expansion of TIL was successful in generating more than 1010 lymphocytes in five of eight consecutive cases. Clinical trials employing the adoptive transfer of expanded TIL to patients with metastatic disease have begun.

UR - http://www.scopus.com/inward/record.url?scp=0023252348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023252348&partnerID=8YFLogxK

M3 - Article

C2 - 3305708

AN - SCOPUS:0023252348

VL - 102

SP - 127

EP - 141

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1

ER -